BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Kidney tumors AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809
1381 results:

  • 1. Giant Renal Angiomyolipomas and Pulmonary Lymphangioleiomyomatosis: Follow-up Report after More than a Decade.
    Nasir K; Ahmad A
    Saudi J Kidney Dis Transpl; 2023 Nov; 34(6):671-675. PubMed ID: 38725217
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. MOICS, a novel classier deciphering immune heterogeneity and aid precise management of clear cell renal cell carcinoma at multiomics level.
    Liu Y; Qi L; Ye B; Wang A; Lu J; Qu L; Luo P; Wang L; Jiang A
    Cancer Biol Ther; 2024 Dec; 25(1):2345977. PubMed ID: 38659199
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. [Total polyphenols of Cydonia oblonga inhibited proliferation and migration of renal cancer cells by PI3K/Akt/mtor pathway].
    Abudurousuli K; Han MY; Hailati S; Maihemuti N; Talihati Z; Nueraihemaiti N; Dilimulati D; Baishan A; Aikebaier A; Zhou WT
    Zhongguo Zhong Yao Za Zhi; 2024 Feb; 49(4):1052-1063. PubMed ID: 38621912
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. VHL mutation drives human clear cell renal cell carcinoma progression through PI3K/AKT-dependent cholesteryl ester accumulation.
    Zhang S; Fang T; He Y; Feng W; Yu Z; Zheng Y; Zhang C; Hu S; Liu Z; Liu J; Yu J; Zhang H; He A; Gong Y; He Z; Yang K; Xi Z; Yu W; Zhou L; Yao L; Yue S
    EBioMedicine; 2024 May; 103():105070. PubMed ID: 38564827
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. An Integrated Machine Learning Framework Identifies Prognostic Gene Pair Biomarkers Associated with Programmed Cell Death Modalities in Clear Cell Renal Cell Carcinoma.
    Chen B; Zhou M; Guo L; Huang H; Sun X; Peng Z; Wu D; Chen W
    Front Biosci (Landmark Ed); 2024 Mar; 29(3):121. PubMed ID: 38538287
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Lymphangioleiomyomatosis in patients with tuberous sclerosis: a national centre audit.
    Johnson J; Somerfield W; Johnson SR
    Orphanet J Rare Dis; 2024 Mar; 19(1):137. PubMed ID: 38532450
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. L1 Cell Adhesion Molecule (L1CAM) Expression and Molecular Alterations Distinguish Low-Grade Oncocytic Tumor From Eosinophilic Chromophobe Renal Cell Carcinoma.
    Alghamdi M; Chen JF; Jungbluth A; Koutzaki S; Palmer MB; Al-Ahmadie HA; Fine SW; Gopalan A; Sarungbam J; Sirintrapun SJ; Tickoo SK; Reuter VE; Chen YB
    Mod Pathol; 2024 May; 37(5):100467. PubMed ID: 38460672
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. The TOPK Inhibitor HI-TOPK-032 Enhances CAR T-cell Therapy of Hepatocellular Carcinoma by Upregulating Memory T Cells.
    Zhang Q; Zheng F; Chen Y; Liang CL; Liu H; Qiu F; Liu Y; Huang H; Lu W; Dai Z
    Cancer Immunol Res; 2024 May; 12(5):631-643. PubMed ID: 38407902
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Hereditary Renal Cancer Syndromes.
    Yanus GA; Kuligina ES; Imyanitov EN
    Med Sci (Basel); 2024 Feb; 12(1):. PubMed ID: 38390862
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. A novel peptide PDHK1-241aa encoded by circPDHK1 promotes ccRCC progression via interacting with PPP1CA to inhibit AKT dephosphorylation and activate the AKT-mtor signaling pathway.
    Huang B; Ren J; Ma Q; Yang F; Pan X; Zhang Y; Liu Y; Wang C; Zhang D; Wei L; Ran L; Zhao H; Liang C; Wang X; Wang S; Li H; Ning H; Ran A; Li W; Wang Y; Xiao B
    Mol Cancer; 2024 Feb; 23(1):34. PubMed ID: 38360682
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Tumorigenic role of tacrolimus through mtorC1/C2 activation in post-transplant renal cell carcinomas.
    Moldvai D; Sztankovics D; Dankó T; Vetlényi E; Petővári G; Márk Á; Patonai A; Végső G; Piros L; Hosszú Á; Pápay J; Krencz I; Sebestyén A
    Br J Cancer; 2024 Apr; 130(7):1119-1130. PubMed ID: 38341510
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Pterostilbene and 6-shogaol exhibit inhibitory effects on sunitinib resistance and motility by suppressing the RLIP76-initiated Ras/ERK and Akt/mtor pathways in renal cancer cells.
    Chiang IC; Chen SY; Hsu YH; Shahidi F; Yen GC
    Eur J Pharmacol; 2024 Mar; 967():176393. PubMed ID: 38325792
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. MAEL in human cancers and implications in prognostication and predicting benefit from immunotherapy over VEGFR/mtor inhibitors in clear cell renal cell carcinoma: a bioinformatic analysis.
    Tao J; Cui J; Xu Y; Fan Y; Hong G; Zhou Q; Wang G; Li L; Han Y; Xu C; Wang W; Cai S; Zhang X
    Aging (Albany NY); 2024 Jan; 16(3):2090-2122. PubMed ID: 38301040
    [No Abstract]    [Full Text] [Related]  

  • 14. Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis.
    Rosellini M; Mollica V; Marchetti A; Coluccelli S; Giunchi F; Tassinari E; Ricci C; Fiorentino M; Tallini G; De Biase D; Massari F
    Pathol Res Pract; 2024 Feb; 254():155142. PubMed ID: 38277752
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Analysis of HIF-1α expression and genetic polymorphisms in human clear cell renal cell carcinoma.
    Vargova D; Kolková Z; Dargaj J; Bris L; Luptak J; Dankova Z; Franova S; Svihra J; Slávik P; Sutovska M
    Pathol Oncol Res; 2023; 29():1611444. PubMed ID: 38273861
    [No Abstract]    [Full Text] [Related]  

  • 16. Cemiplimab for kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma.
    Hanna GJ; Dharanesswaran H; Giobbie-Hurder A; Harran JJ; Liao Z; Pai L; Tchekmedyian V; Ruiz ES; Waldman AH; Schmults CD; Riella LV; Lizotte P; Paweletz CP; Chandraker AK; Murakami N; Silk AW
    J Clin Oncol; 2024 Mar; 42(9):1021-1030. PubMed ID: 38252908
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Effects of Purine Metabolism-Related
    Yin W; Wang JH; Liang YM; Liu KH; Chen Y; Chen YS
    Front Biosci (Landmark Ed); 2023 Dec; 28(12):354. PubMed ID: 38179759
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. ZNF471 Interacts with BANP to Reduce Tumour Malignancy by Inactivating PI3K/AKT/mtor Signalling but is Frequently Silenced by Aberrant Promoter Methylation in Renal Cell Carcinoma.
    Wang X; Yao L; Li Z; Zhang J; Ruan M; Mulati Y; Gan Y; Zhang Q
    Int J Biol Sci; 2024; 20(2):643-663. PubMed ID: 38169650
    [No Abstract]    [Full Text] [Related]  

  • 19. Discovery of novel 1H-benzo[d]imidazole-4,7-dione based transglutaminase 2 inhibitors as p53 stabilizing anticancer agents in renal cell carcinoma.
    Kim GR; Kang JH; Kim HJ; Im E; Bae J; Kwon WS; Rha SY; Chung HC; Cho EY; Kim SY; Kim YC
    Bioorg Chem; 2024 Feb; 143():107061. PubMed ID: 38154386
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Good outcome of liver transplantation in patients with pre-existing renal cell carcinoma.
    Lassailly G; Ningarhari M; Dumortier J; Lafforgue C; Bouye S; Amrani ME; Lebuffe G; Villers A; Truant S; Mathurin P; Louvet A; Boillot O; Boleslawski E; Dharancy S
    Clin Res Hepatol Gastroenterol; 2024 Jan; 48(1):102266. PubMed ID: 38101698
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 70.